source
- PepGen reports positive Phase 2 data for PGN-EDODM1 in myotonic dystrophyPepGen disclosed that its experimental oligonucleotide therapy PGN-EDODM1 showed encouraging early signals in a Phase 2 cohort of patients with myotonic dystrophy type 1 (DM1). The company said the…
- London startup Oyster Therapeutics raises $60M to develop oral tau degraders for Alzheimer’sOyster Therapeutics, a London‑based biotech, announced it has closed a $60 million Series A‑2 financing round. The round was led by 4BIO Capital, a life‑science venture capital firm, with addition…